Clinical Trial

Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients

Study acronym: TAT-t-PAIC
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Primary Objective: To develop a thrombotic event risk assessment model integrating serum biomarkers (TM, TAT, t-PAIC, PIC) with clinical data, systematically compare its predictive performance across healthy populations, vascular surgery patients with acute thrombosis, and dialysis patients, and evaluate its predictive advantages over the Padua Prediction Score and D-dimer. Secondary Objective: To investigate the expression profiles of these four thrombotic biomarkers in different populations and their associations with thrombotic event types and clinical contexts (e.g., duration of dialysis, anticoagulation regimens), identifying independent risk factors and underlying mechanisms to provide a scientific foundation for stratified thrombotic risk management and personalized intervention strategies.
Trial Details
NCT Number NCT07098676
Lead Sponsor Ai Peng
Conditions Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis, Dialysis Patients
Enrollment 900 participants
Start Date 2024-11-20
Primary Completion 2025-05-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-01